Get the Stockscreener App
14.33
0.62%
-0.09
After Hours:
14.33
Janux Therapeutics Inc stock is traded at $14.33, with a volume of 1.23M.
It is down -0.62% in the last 24 hours and down -3.44% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$14.42
Open:
$14.54
24h Volume:
1.23M
Relative Volume:
1.13
Market Cap:
$873.58M
Revenue:
$10.00M
Net Income/Loss:
$-113.63M
P/E Ratio:
-7.8161
EPS:
-1.8334
Net Cash Flow:
$-83.28M
1W Performance:
-1.17%
1M Performance:
-3.44%
6M Performance:
-47.97%
1Y Performance:
-51.90%
1-Day Range:
$14.03
$14.83
1-Week Range:
$13.96
$14.83
52-Week Range:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
14.33 | 879.07M | 10.00M | -113.63M | -83.28M | -1.8334 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | Barclays | Overweight → Underweight |
| Apr-15-26 | Downgrade | UBS | Buy → Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value - Seeking Alpha
EX-99.1 - SEC.gov
JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline - MSN
How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA) - The Globe and Mail
Multiple Insiders Sold Janux Therapeutics Shares Presenting Weak Signs For Investors - simplywall.st
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Point72 affiliates hold 3.07M Janux shares (JANX) — 5.0% stake - Stock Titan
Janux Therapeutics | SCHEDULE 13G: Others - Moomoo
Point72 (NYSE: JANX) entities report 3.07M shares, 5.0% ownership - Stock Titan
Guggenheim Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $68 - Moomoo
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $24 to $68 - Moomoo
Janux ends development of tumor activated T cell engager asset - MSN
Janux Therapeutics halts early stage cancer program in 'prudent' move - MSN
Janux Therapeutics, Inc. Files 8-K Report with SEC: Company Information and Key Disclosures (April 28, 2026) - Minichart
Janux Therapeutics Adjusts Board Class Structure for Director - TipRanks
JonesTrading Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $28 - Moomoo
Janux Therapeutics (NASDAQ: JANX) moves Dobmeier to Class II seat - Stock Titan
Janux Therapeutics | ARS: Annual Report to Security Holders - Moomoo
[ARS] Janux Therapeutics, Inc. SEC Filing - Stock Titan
Janux Therapeutics (JANX) sets 2026 virtual meeting, board elections and pay vote - Stock Titan
JonesTrading Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
BofA cuts Janux Therapeutics stock price target on pipeline changes By Investing.com - Investing.com Canada
Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move - Benzinga
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development - BioSpace
Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57 - MSN
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Janux to Halt Development of Cancer Drug Candidate JANX008 - marketscreener.com
Janux discontinues EGFR-targeted cancer therapy development By Investing.com - Investing.com Canada
Here are the most and least likely M&A targets in biotech, according to Truist - MSN
Janux Therapeutics Announces Collaboration and Exclusive Worldwid - The National Law Review
Janux Therapeutics Inc. (JANX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Janux Therapeutics Inc (JANX) News, Articles, Events & Latest Updates - Stocktwits
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
H.C. Wainwright reiterates Janux Therapeutics stock rating at buy By Investing.com - Investing.com Canada
(JANX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Barclays downgrades Janux Therapeutics (JANX) - MSN
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
Barclays Downgrades Janux Therapeutics(JANX.US) to Sell Rating, Cuts Target Price to $14 - Moomoo
Barclays Downgrades Janux Therapeutics to Underweight From Overweight, Adjusts Price Target to $14 From $29 - marketscreener.com
Barclays cuts Janux Therapeutics stock rating on near-term concerns By Investing.com - Investing.com Canada
HC Wainwright & Co. Reiterates Janux Therapeutics (JANX) Buy Recommendation - MSN
Janux is a new Buy at Truist ahead of catalyst rich H2 - MSN
Janux doses first patient in JANX014 prostate cancer trial By Investing.com - Investing.com Australia
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):